Stock Track | Trevi Therapeutics Soars 7.15% in Pre-Market on Positive Analyst Coverage

Stock Track
03/18

Trevi Therapeutics Inc. (TRVI) experienced a significant pre-market surge of 7.15% on Wednesday, indicating strong investor optimism ahead of the regular trading session.

The upward movement appears to be driven by recent analyst actions. Stifel Nicolaus analyst Annabel Samimy reiterated a Buy rating on the stock and set a price target of $18.00, reinforcing positive sentiment towards the company's prospects.

Concurrently, Morgan Stanley adjusted its outlook, cutting its price target on Trevi Therapeutics to $18.00 from $19.00. Despite the reduction, the maintained target price suggests continued analyst confidence in the stock's value, contributing to the pre-market rally.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10